drugset
drugset / Trial / NCT05088343

Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Subjects

NCT05088343 ↗

Phase 1 Completed 14 enrolled Jiangsu HengRui Medicine Co., Ltd.
NaSequentialOpen-labelBasic science

Summary

Effect of hetrombopag on the pharmacokinetics of rosuvastatin in healthy subjects.

Timeline

Start
2020-09-07
Primary completion
2021-01-16
Completion
2021-01-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Hetrombopag Small molecule 7.5 mg —
Subject Rosuvastatin Small molecule — Oral

Indications

No indication recorded.